Nordic Nanovector ASA (OSE: NANO), a company focusing on the development
and commercialisation of novel targeted therapeutics in haematology and
oncology, announces that its Chief Medical Officer, Cristina Oliva, MD,
has resigned and will leave Nordic Nanovector as per end of January 2016
to pursue other career opportunities in the UK, where she resides with
her family.
The Company has initiated a search for a new CMO and, until a suitable
full-time successor is announced, has engaged the services of a
qualified medical oncologist, trained in the US and specialised in the
treatment of lymphomas, as its Medical Signatory. In addition, the
clinical leadership team will continue to lead the clinical development
activities with support from Nordic Nanovector’s executive team.
“We regret Cristina’s departure but respect her decision,” says Luigi
Costa, CEO of Nordic Nanovector ASA: “Cristina has made a substantial
contribution to the success of the company and is a respected expert
among colleagues, our board and investors. We wish her the best of luck.”
“It has been a very exciting time and I am sad to be leaving the company
at this stage in its development. But I will follow its path and
progress closely,” says Cristina Oliva. “I am convinced that the lead
product Betalutin® will be a success and it has been a privilege working
with the company’s diverse, dedicated and exceptionally competent team.”
About Nordic
Nanovector Nordic Nanovector is a biotech company focusing on the
development and commercialisation of novel targeted therapeutics in
haematology and oncology. The Company’s lead clinical-stage product
opportunity is Betalutin®, the first in a new class of
Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and
complement current options for the treatment of non-Hodgkin Lymphoma
(NHL). NHL is an indication with substantial unmet medical need and
orphan drug opportunities, representing a growing market worth over $12
billion by 2018.
Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1)
conjugated to a low intensity radionuclide (lutetium-177). The
preliminary data has shown promising efficacy and safety profile in an
ongoing Phase 1/2 study in a difficult-to-treat NHL patient population.
The Company is aiming at developing Betalutin® for the treatment of
major types of NHL with first regulatory submission anticipated in 1H
2019.
Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets,
while exploring potential distribution agreements in selected
geographies. The Company is committed to developing its ARC pipeline to
treat multiple selected cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
This information was brought to you by Cision http://news.cision.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20151113005426/en/
Copyright Business Wire 2015